Compare Quest Diagnostics Inc (DGX) vs Zscaler Inc (ZS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Zscaler Inc — how do they compare? Quest Diagnostics Inc trades at $204.9 (market cap $22.80B), while Zscaler Inc trades at $150.55 (market cap $24.59B). The key difference: Quest Diagnostics Inc and Zscaler Inc are close in size by market cap, and Quest Diagnostics Inc pays a 1.67% dividend while Zscaler Inc pays none. Which is the better fit depends on your goals.
| DGX | ZS | |
|---|---|---|
Market Cap | $22.80B | $24.59B |
Sector | Health | Technology |
52-Week High | $216.02 | $336.27 |
52-Week Low | $166.42 | $118.05 |
Enterprise Value | $28.82B | $22.92B |
Dividend Yield | 1.67% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $207.35, showing minimal daily movement with a slight decline of 0.04%. The stock maintains a bullish technical stance with recent earnings beats and analyst consensus pointing to upside potential. Recent developments include New York State approval for Haystack MRD testing and strong momentum across diagnostic channels. Revenue growth accelerated to $11.04 billion in 2025 with consistent profitability margins around 9%.
DGX presents a balanced investment case with 38% analyst buy ratings and a $227.75 price target suggesting 10% upside. The company demonstrates steady revenue growth and operational efficiency, though elevated debt levels and policy risks require monitoring. Second quarter earnings on July 23, 2026, will be crucial for validating current momentum and growth trajectory.
Zscaler trades at $141.82, up 1.83% with bearish technical signals despite recent earnings beats. Revenue growth remains strong at $2.67B for 2025, though the company continues to report net losses. Analyst consensus is overwhelmingly bullish with a $192.64 price target, but multiple class action investigations and high valuation metrics create headwinds.
The stock faces near-term pressure from technical weakness and profitability challenges, but long-term prospects remain supported by cybersecurity demand and Zero Trust adoption. Key risks include ongoing litigation, AI infrastructure costs, and the transition to profitability amid slowing growth projections.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Zscaler Inc
Zscaler is a security-as-a-service firm that offers its customers cloud-delivered solutions for protecting user devices and data. The firm leverages its position in 150 colocation data centers to deliver traditionally appliance-based security functionality, such as firewalls and sandboxes, as a completely cloud-native platform. The firm focuses on large enterprise customers and offers two primary product suites: Zscaler Internet Access, which securely connects users to externally managed application and websites (such as Salesforce and Google), and Zscaler Private Access, which securely connects users to internally managed applications. Both product suites encompass a broad gamut of capabilities situated across the traditional security stack.
Read more on ZS →
